[go: up one dir, main page]

EP3162803A4 - Nouveau composé pour inhiber la liaison entre la protéine dx2 et la protéine p14/arf, et composition pharmaceutique pour le traitement ou la prévention de maladies cancéreuses, comprenant ledit composé en tant que principe actif - Google Patents

Nouveau composé pour inhiber la liaison entre la protéine dx2 et la protéine p14/arf, et composition pharmaceutique pour le traitement ou la prévention de maladies cancéreuses, comprenant ledit composé en tant que principe actif Download PDF

Info

Publication number
EP3162803A4
EP3162803A4 EP15815478.1A EP15815478A EP3162803A4 EP 3162803 A4 EP3162803 A4 EP 3162803A4 EP 15815478 A EP15815478 A EP 15815478A EP 3162803 A4 EP3162803 A4 EP 3162803A4
Authority
EP
European Patent Office
Prior art keywords
protein
treating
pharmaceutical composition
effective ingredient
new compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP15815478.1A
Other languages
German (de)
English (en)
Other versions
EP3162803B1 (fr
EP3162803A2 (fr
Inventor
Bum Joon Park
Gyu Yong Song
Ah-Young OH
Jee-Hyun Lee
Jin-Hyuk HER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Industry Cooperation Foundation of Pusan National University
Industry and Academy Cooperation In Chungnam National University
Original Assignee
University Industry Cooperation Foundation of Pusan National University
Industry and Academy Cooperation In Chungnam National University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020140081396A external-priority patent/KR101636821B1/ko
Priority claimed from KR1020150092057A external-priority patent/KR101679604B1/ko
Application filed by University Industry Cooperation Foundation of Pusan National University, Industry and Academy Cooperation In Chungnam National University filed Critical University Industry Cooperation Foundation of Pusan National University
Priority to EP19189683.6A priority Critical patent/EP3605102B1/fr
Publication of EP3162803A2 publication Critical patent/EP3162803A2/fr
Publication of EP3162803A4 publication Critical patent/EP3162803A4/fr
Application granted granted Critical
Publication of EP3162803B1 publication Critical patent/EP3162803B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
EP15815478.1A 2014-06-30 2015-06-30 Nouveau composé pour inhiber la liaison entre la protéine dx2 et la protéine p14/arf, et composition pharmaceutique pour le traitement ou la prévention de maladies cancéreuses, comprenant ledit composé en tant que principe actif Active EP3162803B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP19189683.6A EP3605102B1 (fr) 2014-06-30 2015-06-30 Utilisation d'une composition comprenant un proteine aimp2-dx2 pour le diagnostic du cancer du poumon

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020140081396A KR101636821B1 (ko) 2014-06-30 2014-06-30 Aimp2-dx2 단백질 또는 이의 단편을 포함하는 폐암 진단용 조성물
KR1020150092057A KR101679604B1 (ko) 2015-06-29 2015-06-29 DX2 단백질과 p14/ARF 단백질 간의 결합을 억제하는 신규 화합물 및 상기 화합물을 유효성분으로 함유하는 암질환 치료 또는 예방용 약학조성물
PCT/KR2015/006701 WO2016003158A2 (fr) 2014-06-30 2015-06-30 Nouveau composé pour inhiber la liaison entre la protéine dx2 et la protéine p14/arf, et composition pharmaceutique pour le traitement ou la prévention de maladies cancéreuses, comprenant ledit composé en tant que principe actif

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP19189683.6A Division EP3605102B1 (fr) 2014-06-30 2015-06-30 Utilisation d'une composition comprenant un proteine aimp2-dx2 pour le diagnostic du cancer du poumon
EP19189683.6A Division-Into EP3605102B1 (fr) 2014-06-30 2015-06-30 Utilisation d'une composition comprenant un proteine aimp2-dx2 pour le diagnostic du cancer du poumon

Publications (3)

Publication Number Publication Date
EP3162803A2 EP3162803A2 (fr) 2017-05-03
EP3162803A4 true EP3162803A4 (fr) 2018-04-04
EP3162803B1 EP3162803B1 (fr) 2019-09-11

Family

ID=55020060

Family Applications (2)

Application Number Title Priority Date Filing Date
EP19189683.6A Active EP3605102B1 (fr) 2014-06-30 2015-06-30 Utilisation d'une composition comprenant un proteine aimp2-dx2 pour le diagnostic du cancer du poumon
EP15815478.1A Active EP3162803B1 (fr) 2014-06-30 2015-06-30 Nouveau composé pour inhiber la liaison entre la protéine dx2 et la protéine p14/arf, et composition pharmaceutique pour le traitement ou la prévention de maladies cancéreuses, comprenant ledit composé en tant que principe actif

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP19189683.6A Active EP3605102B1 (fr) 2014-06-30 2015-06-30 Utilisation d'une composition comprenant un proteine aimp2-dx2 pour le diagnostic du cancer du poumon

Country Status (4)

Country Link
US (2) US10072021B2 (fr)
EP (2) EP3605102B1 (fr)
ES (2) ES2753650T3 (fr)
WO (1) WO2016003158A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102297505B1 (ko) * 2016-03-07 2021-09-01 재단법인 의약바이오컨버젼스연구단 Aimp2-dx2와 hsp70의 결합을 저해하는 항암제 스크리닝 방법
US12186332B2 (en) * 2019-06-27 2025-01-07 Stowers Institute For Medical Research Methods for overcoming WNT/beta-catenin anti-cancer resistance in leukemia stem cells
US12448393B2 (en) 2019-10-30 2025-10-21 Prg S&Tech Inc. Use of novel compound, for preventing, improving or treating amyotrophic lateral sclerosis
CN114748457A (zh) * 2022-04-11 2022-07-15 中国医学科学院医学生物学研究所 一种用于治疗宫颈癌的药物组合物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008004817A1 (fr) * 2006-07-05 2008-01-10 Yong Jin Park Nouveaux dérivés de la décursine et leur utilisation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5876935A (en) 1997-01-08 1999-03-02 Dade Behring Inc. Luminescent specific binding assay
KR100575251B1 (ko) 2003-03-03 2006-05-02 재단법인서울대학교산학협력재단 ｐ38／ＪＴＶ－1을 유효성분으로 하는 암 치료용 약학적조성물 및 암 치료용 약학적 조성물의 스크리닝 방법
US7459529B2 (en) * 2004-11-24 2008-12-02 Seoul National University Industry Foundation AIMP2-DX2 and its uses
US8003780B2 (en) * 2004-11-24 2011-08-23 Neomics Co., Ltd. AIMP2-DX2 gene and SiRNA targeting AIMP2-DX2
KR100715206B1 (ko) 2006-01-19 2007-05-04 박용진 참당귀로부터 데쿨시놀을 고수율로 제조하는 방법
KR101577315B1 (ko) 2013-03-14 2015-12-15 부산대학교 산학협력단 AIMP2-DX2와 p14/ARF의 상호작용을 이용한 암 치료제의 스크리닝 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008004817A1 (fr) * 2006-07-05 2008-01-10 Yong Jin Park Nouveaux dérivés de la décursine et leur utilisation

Also Published As

Publication number Publication date
EP3605102A1 (fr) 2020-02-05
US10280178B2 (en) 2019-05-07
US20180362540A1 (en) 2018-12-20
EP3162803B1 (fr) 2019-09-11
US10072021B2 (en) 2018-09-11
WO2016003158A3 (fr) 2016-02-25
EP3605102B1 (fr) 2021-06-16
WO2016003158A2 (fr) 2016-01-07
ES2880690T3 (es) 2021-11-25
ES2753650T3 (es) 2020-04-13
EP3162803A2 (fr) 2017-05-03
US20170129904A1 (en) 2017-05-11

Similar Documents

Publication Publication Date Title
IL267132B (en) A pharmaceutical preparation for the prevention or treatment of cancer that includes crystalline polymorphs of tetra arsenic hexoxide
PT3616720T (pt) Composição medicinal para tratamento de cancro
IL267074A (en) A pharmaceutical preparation for the prevention or treatment of liver cancer that includes crystalline polymorphs of tetra arsenic hexoxide
EP3481402A4 (fr) Composés, compositions et méthodes de traitement de maladie
EP3675859A4 (fr) Composés, compositions et méthodes pour le traitement d'une maladie
EP3484504A4 (fr) Composés, compositions et méthodes de traitement de maladie
EP3266317A4 (fr) Composition pour prévenir, améliorer ou traiter des troubles neurologiques, contenant un peptide d'osmotine comme principe actif
EP3231436A4 (fr) Composition pharmaceutique pour la prévention ou le traitement d'une maladie métabolique, comprenant des bactéries bacteroides acidifaciens utilisées comme principe actif efficace
SG11201608441YA (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
EP3189849A4 (fr) Nouveau peptide pour l'inhibition de l'accumulation de graisse, et composition pharmaceutique pour prévenir ou traiter l'obésité, comprenant celui-ci
EP3156055A4 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies liées à la faiblesse musculaire contenant du butylpyridinium ou un dérivé de celui-ci
EP3275450A4 (fr) Composition pharmaceutique pour prévenir ou traiter des maladies inflammatoires, contenantlactococcus chungangensis
IL289213A (en) A pharmaceutical preparation for tumor treatment
EP3129378A4 (fr) Composés inhibiteurs de bromodomaine et composition pharmaceutique les comprenant pour prévenir ou traiter un cancer
EP3184113A4 (fr) Composition pharmaceutique comprenant un composé d'or pour la prévention ou le traitement de la fibrose hépatique ou de la cirrhose hépatique
EP3689355A4 (fr) Traitements pharmaceutiques pour prévenir ou traiter le cancer du foie
EP3284743A4 (fr) Composés d'imidazole hétérocycliques, compositions pharmaceutiques les contenant, leur procédé de préparation et utilisation
EP2982378A4 (fr) Composition pour prévenir ou traiter une septicémie ou un choc septique, comprenant la protéine adk comme principe actif
EP3388514A4 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies médiées par des lymphocytes t régulateurs
EP3162803A4 (fr) Nouveau composé pour inhiber la liaison entre la protéine dx2 et la protéine p14/arf, et composition pharmaceutique pour le traitement ou la prévention de maladies cancéreuses, comprenant ledit composé en tant que principe actif
SG11201704766UA (en) Antibacterial composition containing adk protein as active ingredient, or composition for preventing or treating septicemia
KR102316727B9 (ko) 아토피성 질환 예방 또는 치료용 약학적 조성물
GB2579480B (en) Composition for preventing or treating cancer containing Triazolopyridine-based derivative as active ingredient
EP3148570A4 (fr) Composition pharmaceutique destinée à la prévention ou au traitement d'éruptions cutanées
EP3677267A4 (fr) Composition pharmaceutique pour le traitement ou la prévention de tumeurs, méthode et utilisation de celle-ci

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170130

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20171124BHEP

Ipc: C07D 493/04 20060101AFI20171124BHEP

Ipc: A61K 31/35 20060101ALI20171124BHEP

Ipc: G01N 33/574 20060101ALI20171124BHEP

Ipc: A61K 31/34 20060101ALI20171124BHEP

Ipc: C12Q 1/68 20180101ALI20171124BHEP

Ipc: A61K 31/352 20060101ALI20171124BHEP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602015037928

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: C07D0407120000

Ipc: C07D0493040000

A4 Supplementary search report drawn up and despatched

Effective date: 20180307

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20180301BHEP

Ipc: G01N 33/574 20060101ALI20180301BHEP

Ipc: C07D 493/04 20060101AFI20180301BHEP

Ipc: C12Q 1/68 20060101ALI20180301BHEP

Ipc: A61K 31/35 20060101ALI20180301BHEP

Ipc: A61K 31/352 20060101ALI20180301BHEP

Ipc: A61K 31/34 20060101ALI20180301BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190327

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1178320

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190915

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015037928

Country of ref document: DE

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20190911

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191211

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191211

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191212

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2753650

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20200413

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1178320

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190911

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200113

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200224

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602015037928

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG2D Information on lapse in contracting state deleted

Ref country code: IS

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200112

26N No opposition filed

Effective date: 20200615

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200630

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20200630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200630

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200630

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190911

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602015037928

Country of ref document: DE

Owner name: PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY , KR

Free format text: FORMER OWNERS: PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION, BUSAN, KR; THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (IAC), DAEJEON, KR

Ref country code: DE

Ref legal event code: R081

Ref document number: 602015037928

Country of ref document: DE

Owner name: PRG S&TECH INC., KR

Free format text: FORMER OWNERS: PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION, BUSAN, KR; THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (IAC), DAEJEON, KR

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION

Effective date: 20220712

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20220623 AND 20220629

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602015037928

Country of ref document: DE

Owner name: PRG S&TECH INC., KR

Free format text: FORMER OWNER: PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION, BUSAN, KR

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20240411 AND 20240417

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: PRG S&TECH INC.

Effective date: 20241014

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20250605

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20250620

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20250605

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20250718

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20250630

Year of fee payment: 11